Published in J Pharm Sci on January 01, 2011
Recent advances in nonviral vectors for gene delivery. Acc Chem Res (2011) 1.48
Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA. Mol Ther Nucleic Acids (2012) 0.95
A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther (2014) 0.92
RNAi Therapeutic Platforms for Lung Diseases. Pharmaceuticals (Basel) (2013) 0.92
Role of Pharmacovigilance in India: An overview. Online J Public Health Inform (2015) 0.90
Highly specific in vivo gene delivery for p53-mediated apoptosis and genetic photodynamic therapies of tumour. Nat Commun (2015) 0.90
Delivery of intracellular-acting biologics in pro-apoptotic therapies. Curr Pharm Des (2011) 0.87
Systemic tumor-specific gene delivery. J Control Release (2013) 0.84
Questioning the Use of PEGylation for Drug Delivery. Drug Deliv Transl Res (2013) 0.84
Cholesterol domains enhance transfection. Ther Deliv (2013) 0.83
Ligands located within a cholesterol domain enhance gene delivery to the target tissue. J Control Release (2012) 0.83
Antisense 2'-Deoxy, 2'-Fluroarabino Nucleic Acids (2'F-ANAs) Oligonucleotides: In Vitro Gymnotic Silencers of Gene Expression Whose Potency Is Enhanced by Fatty Acids. Mol Ther Nucleic Acids (2012) 0.83
Enhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a xenograft model of colorectal cancer. PLoS One (2012) 0.82
Design of hybrid lipid/retroviral-like particle gene delivery vectors. Mol Pharm (2013) 0.80
Development of a low toxicity, effective pDNA vector based on noncovalent assembly of bioresponsive amino-β-cyclodextrin:adamantane-poly(vinyl alcohol)-poly(ethylene glycol) transfection complexes. Bioconjug Chem (2012) 0.80
Gathering and exploring scientific knowledge in pharmacovigilance. PLoS One (2013) 0.80
In vivo delivery of cell-permeable antisense hypoxia-inducible factor 1α oligonucleotide to adipose tissue reduces adiposity in obese mice. J Control Release (2012) 0.79
Modulation of plasmid DNA vaccine antigen clearance by caspase 12 RNA interference potentiates vaccination. Clin Vaccine Immunol (2011) 0.79
Lyophilization of a triply unsaturated phospholipid: effects of trace metal contaminants. Eur J Pharm Biopharm (2013) 0.78
Rapid and specific post-synthesis modification of DNA through a biocompatible condensation of 1,2-aminothiols with 2-cyanobenzothiazole. Chemistry (2013) 0.78
Improved efficacy and reduced toxicity of doxorubicin encapsulated in sulfatide-containing nanoliposome in a glioma model. PLoS One (2014) 0.77
Synthetic genomics and synthetic biology applications between hopes and concerns. Curr Genomics (2013) 0.77
Whole-body scanning PCR; a highly sensitive method to study the biodistribution of mRNAs, noncoding RNAs and therapeutic oligonucleotides. Nucleic Acids Res (2013) 0.77
Post-synthesis DNA modifications using a trans-cyclooctene click handle. Org Biomol Chem (2015) 0.77
Immunogenicity and safety of xenogeneic vascular endothelial growth factor receptor-2 DNA vaccination in mice and dogs. Oncotarget (2016) 0.76
The effects of lipoplex formulation variables on the protein corona and comparisons with in vitro transfection efficiency. J Control Release (2013) 0.76
In Situ Transfection by Controlled Release of Lipoplexes Using Acoustic Droplet Vaporization. Adv Healthc Mater (2016) 0.76
Relating toxicity to transfection: using sphingosine to maintain prolonged expression in vitro. Mol Pharm (2014) 0.75
Intracellular trafficking of hybrid gene delivery vectors. J Control Release (2015) 0.75
Lipothioureas as Lipids for Gene Transfection: A Review. Pharmaceuticals (Basel) (2011) 0.75
Spatial Control of Gene Expression by Nanocarriers Using Heparin Masking and Ultrasound-Targeted Microbubble Destruction. ACS Nano (2016) 0.75
pH-responsive biodegradable assemblies containing tunable phenyl-substituted vinyl ethers for use as efficient gene delivery vehicles. ACS Appl Mater Interfaces (2013) 0.75
Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides. Nucleic Acid Ther (2015) 0.75
Trigger-Responsive Gene Transporters for Anticancer Therapy. Nanomaterials (Basel) (2017) 0.75
Complement C3-dependent uptake of targeted liposomes into human macrophages, B cells, dendritic cells, neutrophils, and MDSCs. Int J Nanomedicine (2017) 0.75
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A (1987) 18.91
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 12.75
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science (2000) 10.40
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09
Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science (2009) 8.80
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol (2008) 6.81
Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A (2008) 5.76
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A (2008) 4.57
Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett (2009) 4.45
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res (2006) 4.43
Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry (1996) 4.06
Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm (2008) 3.92
The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm (2009) 3.49
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A (2007) 3.30
Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther (2005) 3.28
Condensation of DNA by multivalent cations: considerations on mechanism. Biopolymers (1991) 2.96
PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther (1999) 2.90
Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A (1988) 2.74
A transition to a compact form of DNA in polymer solutions. Proc Natl Acad Sci U S A (1971) 2.64
Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci U S A (1989) 2.55
Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther (2009) 2.39
Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A (1993) 2.35
On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther (2001) 2.35
A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther (2000) 2.26
Introduction of liposome-encapsulated SV40 DNA into cells. J Biol Chem (1980) 2.23
China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst (2006) 2.20
Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm (2002) 2.06
Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther (2008) 2.02
Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci U S A (1994) 1.98
Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry (2004) 1.91
Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther (1996) 1.87
A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res (2005) 1.83
Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta (1994) 1.82
Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta (2001) 1.78
CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol (2008) 1.73
Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release (2007) 1.68
A novel mechanism is involved in cationic lipid-mediated functional siRNA delivery. Mol Pharm (2009) 1.68
Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm (2009) 1.65
Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys J (2001) 1.64
Overcoming the innate immune response to small interfering RNA. Hum Gene Ther (2008) 1.64
Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm (2002) 1.58
Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther (2002) 1.57
Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta (2007) 1.56
Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo. Adv Drug Deliv Rev (1998) 1.55
Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther (2001) 1.55
Non-viral is superior to viral gene delivery. J Control Release (2007) 1.54
Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J Control Release (2003) 1.54
Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep (2002) 1.53
Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther (2006) 1.51
Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res (2005) 1.51
Nonviral methods for siRNA delivery. Mol Pharm (2009) 1.50
Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta (1992) 1.50
DNA toroids: stages in condensation. Biochemistry (1999) 1.49
Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: implications for intravenous lipofection. Gene Ther (1999) 1.47
Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm (2007) 1.43
Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol (1999) 1.41
Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther (2001) 1.40
Liposome-mediated delivery of deoxyribonucleic acid to cells: enhanced efficiency of delivery related to lipid composition and incubation conditions. Biochemistry (1981) 1.39
Structure and gene silencing activities of monovalent and pentavalent cationic lipid vectors complexed with siRNA. Biochemistry (2007) 1.36
Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release (2006) 1.36
PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release (2007) 1.34
Stabilized plasmid-lipid particles: construction and characterization. Gene Ther (1999) 1.33
Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther (2000) 1.32
Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R). Bioconjug Chem (2007) 1.31
The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids (1990) 1.31
Hydrolytic degradation of poly(ethylene oxide)-block-polycaprolactone worm micelles. J Am Chem Soc (2005) 1.30
Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release (2007) 1.27
Mechanism of plasmid delivery by hydrodynamic tail vein injection. I. Hepatocyte uptake of various molecules. J Gene Med (2006) 1.25
Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochim Biophys Acta (1998) 1.24
Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug Chem (2003) 1.24
Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther (2004) 1.23
Overcoming the inhibitory effect of serum on lipofection by increasing the charge ratio of cationic liposome to DNA. Gene Ther (1997) 1.21
DNA condensation for gene therapy as monitored by atomic force microscopy. Nucleic Acids Res (1998) 1.20
Low-pH-sensitive poly(ethylene glycol) (PEG)-stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery. J Gene Med (2005) 1.19
Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci (2000) 1.18
Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo. Biochim Biophys Acta (1994) 1.17
Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. J Control Release (2003) 1.16
A compact form of double-stranded DNA in solution. FEBS Lett (1972) 1.15
Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9-dependent and -independent pathways. J Leukoc Biol (2004) 1.15
Inclusion of cholesterol in DOTAP transfection complexes increases the delivery of DNA to cells in vitro in the presence of serum. Gene Ther (1998) 1.14
Polymer-protein interactions. Comparison of experiment and excluded volume theory. J Biol Chem (1983) 1.13
Characterization of liposome-mediated gene delivery: expression, stability and pharmacokinetics of plasmid DNA. Gene Ther (1997) 1.12
Liposome-mediated delivery of tobacco mosaic virus RNA into tobacco protoplasts: A sensitive assay for monitoring liposome-protoplast interactions. Proc Natl Acad Sci U S A (1982) 1.11
Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta (1998) 1.11
Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther (2000) 1.10
Steric stabilization of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes mediates prolonged circulation and tumor targeting in mice. J Gene Med (2004) 1.10
Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev (2005) 1.10
Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat Biotechnol (1999) 1.10
Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle. J Cell Sci (1992) 1.09
The role of lipid charge density in the serum stability of cationic lipid/DNA complexes. Biochim Biophys Acta (2004) 1.08
Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim Biophys Acta (1993) 1.08
In vivo comparative study of lipid/DNA complexes with different in vitro serum stability: effects on biodistribution and tumor accumulation. J Pharm Sci (2008) 1.08
Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit Rev Ther Drug Carrier Syst (1992) 1.06
The promise of nucleic acid vaccines. Gene Ther (2000) 1.05
Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am J Physiol (1999) 1.05
PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting efficacy. J Drug Target (2008) 1.04
Optimization of cell surface binding enhances efficiency and specificity of molecular conjugate gene delivery. J Biol Chem (1998) 1.03
Micelles from polyethylene glycol/phosphatidylethanolamine conjugates for tumor drug delivery. J Control Release (2003) 1.03